Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 182

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 182
---
 510,695                          Net loss for the year  -   -   -   (2,629,043 )  -   (2,629,043 )                         Foreign currency translation loss  -   -   -   -   (268,232 )  (268,232 )                         Balance as of December 31, 2023  17,667,663  $17,191,315  $(5,011,891 ) $(1,844,278 ) $(677,294 ) $9,657,852 

Share activity (number of shares or both number and amount of shares) has been adjusted for the periods shown to reflect the 12-for-1 reverse stock split effected on July 20, 2023, on a retroactive basis

* 1,437,500 shares of common stock were issued to the underwriter.

# 834,299 shares of common stock were issued to professional parties and board members

  Common stock                     Accumulated       Number of     Additionalpaid in   Accumulated  other comprehensive  Totalstockholders’   shares  Amount  capital  deficit  (losses)/gain  equity                    Balance as of January 1, 2024   17,667,663  $17,191,315  $(5,011,891 ) $(1,844,278 ) $(677,294 ) $9,657,852                          Issuance of shares@  300,000   141,000   -   -   -   141,000                          Net loss for the year  -   -   -   (1,598,342)  -   (1,598,342)                         Foreign currency translation gain  -   -   -   -   122,294   122,294                          Balance as of December 31, 2024  17,967,663  $17,332,315  $(5,011,891 ) $(3,442,620) $(555,000) $8,322,804 

@